| Date |
Subject |
Media |
| 2025-08-27 |
Silver Economy Emerging as New Blue Ocean: Top 10 Senior-Friendly Innovative Technologies Announced
|
As Taiwan enters a super-aged society, the silver economy is booming with unprecedented business opportunities. The latest selection of the “Top 10 Senior-Friendly Technology Products” has been unveiled, highlighting innovative solutions such as National Taiwan University Hospital Yunlin Branch’s Smart Indoor Positioning System, UGYM Technology’s Pain Relief Electrotherapy Device, imedtac’s Automated Bathing Machine, and CTBC Bank’s Senior-Friendly ATM with AI-powered fraud prevention. Industry experts believe these innovations not only showcase Taiwan’s strong R&D capabilities but also demonstrate international competitiveness, serving as important indicators for investment and industrial transformation. |
| 2025-08-27 |
Formosa Biomedical Technology and Rohto Pharmaceutical Sign Strategic Partnership to Expand Regenerative Medicine Market in Taiwan and Japan
|
Formosa Biomedical Technology announced on August 1 that, on behalf of Formosa Plastics Group’s regenerative medicine ecosystem—including IVY LIFE SCIENCE—the company signed a strategic partnership agreement with Japan’s globally renowned Rohto Pharmaceutical Co., Ltd. on July 22, marking the beginning of a deep collaboration in regenerative medicine between Taiwan and Japan. |
| 2025-08-27 |
Protect Animal Health Incorporation to Debut on Emerging Stock Board August 4 at NT$33 per Share, Targeting the Billion-Dollar Senior Pet Medicine Market
|
Protect Animal Health Incorporation, an innovative veterinary drug developer, is set to debut on Taiwan’s Emerging Stock Board on August 4 with a broker-underwritten reference price of NT$33 per share. Leveraging its “Moneyball Strategy,” platform-based incubation capabilities, and global partnerships, Protect is advancing three high-value therapeutic areas: cancer immunotherapy vaccines, gene therapy for heart disease, and an antibody drug platform. Together, these markets are valued at nearly NT$20 billion (approximately US$660 million). Its lead candidate, PT001, a novel melanoma vaccine, has already filed for field trials and will first be developed in Taiwan before expanding to global markets. |
| 2025-08-12 |
UnicoCell Biomed Advances Main Board Listing Plans, Focusing on Irreversible Diseases in Regenerative Medicine
|
UnicoCell Biomed, a key player in the field of regenerative medicine, has officially launched its plan to transfer its listing to Taiwan’s main board. The company is currently focused on regenerative treatments for irreversible diseases. Among its core pipelines, the chronic kidney disease (CKD) therapy is expected to file for a Phase III clinical trial in Taiwan next year, while overseas licensing discussions are also underway. In addition, patient enrollment for its Phase III clinical trial targeting knee osteoarthritis is anticipated to be completed by the end of this year. Meanwhile, UnicoCell is expanding the scientific data surrounding its exosome technology for both aesthetic and therapeutic applications, broadening the scope of its raw material offerings. |
| 2025-08-12 |
New Power Joins Taiwan’s Vaccine National Team: NHRI Spin-Off "TaiU Biotech" Secures NT$60 Million in Seed Funding Led by Mosaic Seed Fund
|
A new force has joined Taiwan’s vaccine national team. TaiU Biotech, a startup spun off from the National Health Research Institutes (NHRI), announced yesterday (July 31) that it has successfully closed a NT$60 million seed funding round with support from Mosaic Venture Lab. The round was led by the Mosaic Seed Fund, and with assistance from the Small and Medium Enterprise and Startup Administration of the Ministry of Economic Affairs and the National Innovation and Entrepreneurship Association, TaiU also secured co-investment from the National Development Fund. |
| 2025-08-12 |
BIONET Therapeutics’ UCMSC Exosome Drug Substance Receives FDA DMF Type II Registration Approval
|
BIONET Therapeutics, a subsidiary of BIONET Corp., announced that it has received notification from the U.S. Food and Drug Administration (FDA) approving the Drug Master File (DMF) Type II registration for its proprietary umbilical cord mesenchymal stem cell (UCMSC) exosome drug substance. |
| 2025-08-12 |
Foresee Pharmaceuticals Files for CAMCEVI Launch in Singapore
|
Foresee Pharmaceuticals announced that its licensing partner, Changchun GeneScience Pharmaceutical, has submitted a marketing application to Singapore’s Health Sciences Authority (HSA) for CAMCEVI 42mg, a new formulation developed for the treatment of prostate cancer. |
| 2025-08-12 |
KMUH Achieves HIMSS EMRAM Stage 7 Certification
|
In response to the digital wave driven by big data and artificial intelligence (AI), Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) has achieved Stage 7 of the Electronic Medical Record Adoption Model (EMRAM) certification by the Healthcare Information and Management Systems Society (HIMSS)—the highest international recognition in medical information management systems. KMUH is the first medical institution in southern Taiwan to receive this prestigious honor. |
| 2025-08-12 |
Biomedica Corporation Secures Thai Medical Certification in Just Eight Months—Reveals Three Core Strategies for Market Entry
|
Biomedica Corporation, which has actively expanded into international markets in recent years, has achieved notable success in Thailand. During the “New Southbound Healthcare Market Expansion Experience Sharing Session,” Biomedica’s Founder and Chief Marketing Officer, Ming-Hsiang Lin, shared how the company successfully obtained TFDA (Thai Food and Drug Administration) certification in just eight months. He also revealed for the first time the company’s three core strategies for entering the Thai market—offering valuable insights for medical startups targeting Southeast Asia. |
| 2025-08-12 |
Blueprint for a Super-Aged Future City: Experts Share Insights at the “Age-Friendly Cities Forum”
|
“I came to confess on July 30—our urban planning has fallen behind, because we had no prior experience with such longevity!” joked LIN, CHIEN YUAN, Professor at the Graduate Institute of Building and Planning, National Taiwan University. His comment, though made with a touch of humor, rang a serious alarm: it’s time for everyone to address the realities of a super-aged society. |
